================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C. 20549-1004

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

          DATE OF REPORT (date of earliest event reported): MAY 4, 2006

                           CIPHERGEN BIOSYSTEMS, INC.
             (Exact name of Registrant as specified in its charter)

              Delaware                 000-31617            33-059-5156
   (State or other jurisdiction of    [Commission        (I.R.S. Employer
   incorporation or organization)     File Number]     Identification Number)

                              6611 Dumbarton Circle
                                Fremont, CA 94555
                    (Address of principal executive offices)

                                 (510) 505-2100
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2.):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting materials pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 2.02   RESULTS OF OPERATIONS AND FINANCIAL CONDITION

         On May 4, 2006, Ciphergen Biosystems, Inc. issued a press release
announcing financial results for its fiscal first quarter ended March 31, 2006.
The press release is attached as Exhibit 99.1 to this Form 8-K.

         The information in this Current Report on Form 8-K is being furnished
and shall not be deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section.

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS

(d)  Exhibits.

EXHIBIT NO.    DESCRIPTION
-----------    -----------------------------------------------------------------
99.1           Press Release issued by Ciphergen Biosystems, Inc. on May 4, 2006



                                    SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       CIPHERGEN BIOSYSTEMS, INC.
                                       (Registrant)


Date: May 4, 2006                      By: /S/ GAIL S. PAGE
                                           -------------------------------------
                                           Gail S. Page
                                           President and Chief Executive Officer



                                  EXHIBIT INDEX

EXHIBIT
NUMBER                                  DESCRIPTION
-------    ---------------------------------------------------------------------
 99.1      Press Release issued by Ciphergen Biosystems, Inc. on May 4, 2006